The International Myeloma Foundation is dedicated to improving the lives of multiple myeloma patients while working toward
prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Multiple myeloma patient and IMF Support Group Leader Tiffany Williams advocates in South Carolina for the Cancer Drug Parity Act of 2019. As she says about oral chemotherapy medications, “Some patients don’t have access to these life-saving medications. That has to change.”
The Phase 3 TOURMALINE-MM4 study has met its primary endpoint of progression free survival (PFS). "The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation."
Details about co-pay assistance programs for multiple myeloma patients.
On November 16, 2019, the IMF will host a Regional Community Workshop in Columbia, MD. Click here to learn more.
Anticipation surrounded Wednesday’s preview of hundreds of new myeloma research studies that will be presented at the American Society of Hematology (ASH) Annual Meeting in Orlando in a few weeks.
In this week’s video, Dr. Durie discusses how bone marrow testing is currently used and if there is a potential for blood testing to eventually replace bone marrow testing for multiple myeloma.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.